300 results on '"Hu, Hong-Ming"'
Search Results
2. A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count
3. 680 Multi-parametric assessment of the immune response to a trio immunotherapy in patients with recurrent or metastatic head and neck squamous cell carcinoma
4. Blocking immunoinhibitory receptor LILRB2 reprograms tumor-associated myeloid cells and promotes antitumor immunity
5. Activating the Nucleic Acid-Sensing Machinery for Anticancer Immunity
6. Abstract CT123: Trial in progress: First-in-human immunotherapy-trio for advanced head and neck squamous cell carcinoma
7. Supplementary Figure 1 from Tumor-Derived Autophagosome Vaccine: Induction of Cross-Protective Immune Responses against Short-lived Proteins through a p62-Dependent Mechanism
8. Supplementary Figure 3 from Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy
9. Supplementary Figure 2 from Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy
10. Supplementary Figure 4 from Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy
11. Supplementary Figure 1 from Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy
12. Supplementary Figure 5 from Tumor-Derived Autophagosome Vaccine: Mechanism of Cross-Presentation and Therapeutic Efficacy
13. Data from The Vitamin E Analogue α-TEA Stimulates Tumor Autophagy and Enhances Antigen Cross-Presentation
14. Supplementary Figure 1 from The Vitamin E Analogue α-TEA Stimulates Tumor Autophagy and Enhances Antigen Cross-Presentation
15. Data from Efficient Cross-presentation Depends on Autophagy in Tumor Cells
16. Supplementary Methods, Figure Legend 1 from The Vitamin E Analogue α-TEA Stimulates Tumor Autophagy and Enhances Antigen Cross-Presentation
17. Supplementary Figures 1-4 from Efficient Cross-presentation Depends on Autophagy in Tumor Cells
18. Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism
19. Tumor-released autophagosomes induces CD4+ T cell-mediated immunosuppression via a TLR2–IL-6 cascade
20. SPIO Enhance the Cross-Presentation and Migration of DCs and Anionic SPIO Influence the Nanoadjuvant Effects Related to Interleukin-1β
21. Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1
22. Additional file 2 of A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count
23. Additional file 1 of A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count
24. Expansion of KRAS hotspot mutations reactive T cells from human pancreatic tumors using autologous T cells as the antigen-presenting cells
25. A simple and effective method to purify and activate T cells for successful generation of chimeric antigen receptor T (CAR-T) cells from patients with high monocyte count.
26. 113 Uncovering the dark immunopeptidome of head and neck squamous cell carcinoma (HNSCC): relevance for universal cancer vaccines, immunological monitoring and TIL therapy
27. 5 Development of a vaccine to intercept oral cancer
28. 1171 CAN1012: a selective and potent TLR7 agonist with strong antitumoral properties mediated by localized innate immune activation
29. OX40 agonist stimulation increases and sustains humoral and cell-mediated responses to SARS-CoV-2 protein and saRNA vaccines
30. Undefined-Antigen Vaccines
31. Expansion of KRAS hot spot mutations reactive T cells from human pancreatic tumors using autologous T-cells as the antigen-presenting cells
32. Abstract CT502: Preliminary immunological monitoring of first-in-human immunotherapy-trio for advanced head and neck squamous cell carcinoma
33. OX40 boosts and sustains humoral and cellular immune responses to SARS-CoV2 spike protein and RNA vaccinations
34. 85 Detection of human angiotensin-converting enzyme 2 receptor (hACE2R) on human cancer cell lines
35. Macrophages enhance tumor-derived autophagosomes (DRibbles)-induced B cells activation by TLR4/MyD88 and CD40/CD40L
36. Development and characterization of recombinant human Fc:OX40L fusion protein linked via a coiled-coil trimerization domain
37. Immunotherapy for melanoma: The good, the bad, and the future
38. Regression of bone metastases following adoptive transfer of anti-CD3-activated and IL-2-expanded tumor vaccine draining lymph node cells
39. Targeting regulatory T cells and other strategies to enable cancer vaccines
40. 443 An immunotherapy trio in advanced HNSCC for coordinated B and T cell antigen response
41. 480 Preliminary evaluation of a novel coronavirus vaccine (CORVax) using electroporation of plasmid DNA encoding a stabilized prefusion SARS-CoV-2 spike protein alone or with transfection of plasmid IL-12
42. Blockade of the Phagocytic Receptor MerTK on Tumor-Associated Macrophages Enhances P2X7R-Dependent STING Activation by Tumor-Derived cGAMP
43. MOESM1 of Peritumoral administration of DRibbles-pulsed antigen-presenting cells enhances the antitumor efficacy of anti-GITR and anti-PD-1 antibodies via an antigen presenting independent mechanism
44. Additional file 2: of Tumor-released autophagosomes induces CD4+ T cell-mediated immunosuppression via a TLR2–IL-6 cascade
45. Additional file 1: of Tumor-released autophagosomes induces CD4+ T cell-mediated immunosuppression via a TLR2â IL-6 cascade
46. Adjuvant Immunization of HLA-A2–Positive Melanoma Patients With a Modified gp100 Peptide Induces Peptide-Specific CD8+ T-Cell Responses
47. Tumour-induced polarization of tumour vaccine-draining lymph node T cells to a type 1 cytokine profile predicts inherent strong immunogenicity of the tumour and correlates with therapeutic efficacy in adoptive transfer studies
48. Additional file 2: of Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1
49. Additional file 1: of Tumor cell-released autophagosomes (TRAPs) promote immunosuppression through induction of M2-like macrophages with increased expression of PD-L1
50. IMMUNE DEVIATION: A POSSIBLE MECHANISM TO PREVENT TUMOR DESTRUCTION.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.